Dr. Enos Bernasconi

Biography

Enos Bernasconi's research focuses primarily on HIV infection, with significant contributions to the Swiss HIV Cohort Study. His work has demonstrated the potential to abandon primary Pneumocystis jiroveci pneumonia in individuals with advanced HIV disease, showing an increase in CD4+ counts to over 200 cells/uL with potent antiretroviral treatment within six months. He has also advanced the understanding of lipoatrophy, an adverse event associated with antiretroviral therapy, clarifying that it is caused more so by thymidine analogues than by HIV-protease inhibitors. His extensive review of biological and epidemiological studies established that individuals with effective antiretroviral treatment and undetectable HIV-viremia do not transmit the virus through sexual intercourse. Furthermore, he has contributed to interventional studies aimed at the micro-elimination of hepatitis C among men who have sex with men, and he has demonstrated the efficacy and safety of dual antiretroviral therapy as an alternative to classic drug combinations. More recently, his collaborative efforts aim to understand HIV transmission networks to guide prevention initiatives and he continues to contribute to studies on HIV resistance and viral genetic determinants related to HIV pathogenesis and immune response.

Research Interests

Experience